← Back to Screener
Voyager Therapeutics, Inc. Common Stock (VYGR)
Price$4.23
Favorite Metrics
Price vs S&P 500 (26W)-26.15%
Price vs S&P 500 (4W)-2.08%
Market Capitalization$252.11M
All Metrics
Book Value / Share (Quarterly)$3.32
P/TBV (Annual)5.09x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-0.43%
Cash Flow / Share (Quarterly)$-2.29
Price vs S&P 500 (YTD)0.95%
Net Profit Margin (TTM)-296.53%
EPS (TTM)$-2.04
10-Day Avg Trading Volume0.66M
EPS Excl Extra (TTM)$-2.04
Revenue Growth (5Y)-25.08%
EPS (Annual)$-2.04
ROI (Annual)-61.06%
Net Profit Margin (5Y Avg)-125.73%
Cash / Share (Quarterly)$3.33
Revenue Growth QoQ (YoY)144.28%
ROA (Last FY)-47.46%
Revenue Growth TTM (YoY)-49.53%
EBITD / Share (TTM)$-2.15
ROE (5Y Avg)-36.05%
Operating Margin (TTM)-326.56%
Cash Flow / Share (Annual)$-2.29
P/B Ratio1.29x
P/B Ratio (Quarterly)1.11x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)4.63x
Net Interest Coverage (TTM)-177.00x
ROA (TTM)-39.38%
EV / EBITDA (TTM)13.01x
EPS Incl Extra (Annual)$-2.04
Current Ratio (Annual)7.64x
Quick Ratio (Quarterly)7.47x
3-Month Avg Trading Volume0.65M
52-Week Price Return31.95%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$4.01
P/S Ratio (Annual)6.24x
Asset Turnover (Annual)0.16x
52-Week High$5.55
Operating Margin (5Y Avg)-140.57%
EPS Excl Extra (Annual)$-2.04
CapEx CAGR (5Y)-26.50%
Tangible BV CAGR (5Y)-15.13%
26-Week Price Return-17.40%
Quick Ratio (Annual)7.60x
13-Week Price Return0.00%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)7.64x
Enterprise Value$186.805
Revenue / Share Growth (5Y)-31.58%
Asset Turnover (TTM)0.13x
Book Value / Share Growth (5Y)-4.25%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-296.17%
Cash / Share (Annual)$3.33
3-Month Return Std Dev71.02%
Net Income / Employee (TTM)$-1
ROE (Last FY)-61.06%
EPS Basic Excl Extra (Annual)$-2.04
P/FCF (TTM)4.45x
Receivables Turnover (TTM)19.73x
EV / Free Cash Flow (TTM)0.90x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.04
Receivables Turnover (Annual)19.73x
ROI (TTM)-51.35%
P/S Ratio (TTM)6.24x
Pretax Margin (5Y Avg)-125.38%
Revenue / Share (Annual)$0.69
Tangible BV / Share (Annual)$1.53
Price vs S&P 500 (52W)-3.15%
Year-to-Date Return5.09%
5-Day Price Return7.55%
EPS Normalized (Annual)$-2.04
ROA (5Y Avg)-18.43%
Net Profit Margin (Annual)-296.53%
Month-to-Date Return6.99%
Cash Flow / Share (TTM)$1.34
EBITD / Share (Annual)$-2.15
Operating Margin (Annual)-326.56%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-36.05%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-2.04
P/TBV (Quarterly)1.71x
P/B Ratio (Annual)1.11x
Pretax Margin (TTM)-296.17%
Book Value / Share (Annual)$3.32
Price vs S&P 500 (13W)-2.87%
Beta1.36x
P/FCF (Annual)3.38x
Revenue / Share (TTM)$0.69
ROE (TTM)-51.35%
52-Week Low$2.65
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.39
4.39
4.39
4.39
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
VYGRVoyager Therapeutics, Inc. Common Stock | 6.24x | -49.53% | — | — | $4.23 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Voyager Therapeutics is a gene therapy company developing AAV-based treatments for severe neurological diseases. The company's proprietary TRACER platform enables the engineering, optimization, and delivery of therapies designed to achieve durable efficacy following single-dose administration. Its pipeline includes programs targeting tau-related neurodegeneration, SOD1 overexpression disorders, and Friedreich's ataxia.